Your browser is no longer supported. Please, upgrade your browser.
Auris Medical Holding Ltd.
Index- P/E- EPS (ttm)-1.46 Insider Own4.43% Shs Outstand12.87M Perf Week4.88%
Market Cap33.20M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.20M Perf Month-19.30%
Income-9.00M PEG- EPS next Q- Inst Own1.70% Short Float6.93% Perf Quarter-14.25%
Sales0.17M P/S190.29 EPS this Y40.20% Inst Trans22.15% Short Ratio0.15 Perf Half Y266.98%
Book/sh2.48 P/B1.21 EPS next Y- ROA-66.00% Target Price- Perf Year242.05%
Cash/sh1.12 P/C2.68 EPS next 5Y- ROE-90.50% 52W Range0.73 - 6.60 Perf YTD14.89%
Dividend- P/FCF- EPS past 5Y62.50% ROI- 52W High-54.39% Beta1.38
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low314.89% ATR0.43
Employees9 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)42.99 Volatility17.51% 10.75%
OptionableYes Debt/Eq0.03 EPS Q/Q69.10% Profit Margin- Rel Volume0.13 Prev Close3.21
ShortableYes LT Debt/Eq0.00 EarningsMar 31 BMO Payout- Avg Volume5.49M Price3.01
Recom- SMA20-7.97% SMA50-15.23% SMA20033.95% Volume701,359 Change-6.23%
Oct-08-18Initiated Euro Pacific Capital Buy $2.50
Apr-13-17Initiated ROTH Capital Buy $4.50
Aug-19-16Reiterated Needham Buy $11 → $5
Sep-09-14Initiated Needham Buy $11
May-07-21 09:05AM  
Apr-13-21 07:45AM  
Apr-08-21 08:00AM  
Mar-31-21 08:30AM  
Mar-24-21 08:00AM  
Jan-29-21 08:30AM  
Dec-15-20 08:30AM  
Dec-09-20 12:45AM  
Dec-07-20 04:10PM  
Dec-02-20 08:45AM  
Dec-01-20 09:00AM  
Nov-20-20 09:10AM  
Oct-15-20 10:26AM  
Oct-13-20 10:36AM  
Sep-17-20 08:00AM  
Sep-11-20 08:00AM  
Sep-08-20 08:30AM  
Sep-03-20 08:30AM  
Aug-20-20 04:30PM  
Jul-29-20 08:30AM  
May-26-20 08:30AM  
May-10-20 10:39AM  
Apr-16-20 07:00AM  
Apr-03-20 05:00PM  
Mar-26-20 06:00AM  
Mar-19-20 06:00AM  
Mar-05-20 08:30AM  
Feb-25-20 08:30AM  
Feb-10-20 10:01AM  
Jan-10-20 08:30AM  
Dec-30-19 08:30AM  
Nov-11-19 10:05AM  
Oct-11-19 08:30AM  
Sep-13-19 09:00AM  
Sep-11-19 09:00AM  
Sep-04-19 07:00AM  
Aug-26-19 09:00AM  
Aug-23-19 10:21AM  
Aug-22-19 10:06AM  
Aug-15-19 07:00AM  
Jul-30-19 08:30AM  
Jul-03-19 09:00AM  
Jun-13-19 09:50AM  
May-23-19 09:00AM  
May-20-19 08:45AM  
May-17-19 04:55PM  
May-15-19 04:15PM  
May-13-19 08:30AM  
May-07-19 09:00AM  
Apr-30-19 08:30AM  
Apr-25-19 09:00AM  
Apr-18-19 12:11PM  
Apr-15-19 09:00AM  
Mar-29-19 09:01AM  
Mar-14-19 09:48PM  
Mar-11-19 08:51AM  
Mar-07-19 08:01AM  
Feb-13-19 10:42AM  
Feb-08-19 05:00PM  
Feb-01-19 07:31AM  
Jan-29-19 07:31AM  
Jan-23-19 09:45AM  
Jan-15-19 08:31AM  
Dec-06-18 09:15AM  
Nov-26-18 09:00AM  
Nov-23-18 07:40AM  
Nov-21-18 07:00AM  
Nov-20-18 09:20AM  
Nov-15-18 07:22AM  
Nov-08-18 07:00AM  
Nov-02-18 08:00AM  
Nov-01-18 12:00PM  
Oct-17-18 06:45AM  
Oct-16-18 08:00AM  
Oct-15-18 04:32PM  
Oct-12-18 07:30AM  
Oct-09-18 08:10AM  
Aug-30-18 08:16AM  
Aug-15-18 06:59AM  
Aug-09-18 08:01AM  
Jul-13-18 07:40AM  
Jul-12-18 08:00PM  
Jul-03-18 08:01AM  
Jun-13-18 07:05AM  
Jun-04-18 12:34PM  
May-30-18 07:45AM  
May-22-18 10:13PM  
May-15-18 06:56AM  
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.